` Comparison: 086890 vs ATXS - Alpha Spread

I
086890
vs
ATXS

Over the past 12 months, Isu Abxis Co Ltd has underperformed ATXS, delivering a return of -2% compared to the ATXS's +91 569% growth.

Start AI Comparison

Smart Verdict
AI-Powered

Not Sure Which Stock Wins?
Let AI Decide.
086890
ATXS
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Smart Verdict is Ready!
See Who Stands Out.
All the numbers, charts, and metrics summarized into one smart verdict.
Stocks Compared:
Show Comparison Results
Summarizing...
We need a little more time to summarize the results

Valuation Comparison

I
Intrinsic Value
8 635.41 KRW
Undervaluation 35%
Intrinsic Value
Price
ATXS Intrinsic Value
0.16 USD
Overvaluation 100%
Intrinsic Value
Price
Company Last Price Intrinsic Value DCF Value Relative Value Wall St Target
I
Isu Abxis Co Ltd
KOSDAQ:086890
5 570 KRW
Astria Therapeutics Inc
NASDAQ:ATXS
5 784.3 USD
No Stocks Selected

Compare the stock's valuation with its competitors.

Select Stocks to Compare
Valuation Scenario:
Bear Case
Base Case
Bull Case

Growth Comparison

Growth Over Time
086890, ATXS

086890
ATXS
Add Stock
Revenue
www.alphaspread.com
No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare
Company LTM Historical Growth Growth Streak % Positive Years Max Drawdown Volatility Forecasted Growth
3 Years 5 Years 10 Years 1 Year 3 Years
I
Isu Abxis Co Ltd
Revenue
Astria Therapeutics Inc
Revenue

All metrics are calculated based on data from the last 10 years.

No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare

Profitability Comparison

Free Cash Flow
086890, ATXS

086890
ATXS
Add Stock
Free Cash Flow
www.alphaspread.com
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
Company LTM Average Historical Growth FCF Margin Conversion
3 Years 5 Years 3 Years 5 Years 10 Years
I
Isu Abxis Co Ltd
KOSDAQ:086890
Astria Therapeutics Inc
NASDAQ:ATXS
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
What is Free Cash Flow?

Gross Margin

Isu Abxis Co Ltd
65.9%
ATXS
0%

Operating Margin

Isu Abxis Co Ltd
22.2%
ATXS
-19 335.7%

Net Margin

Isu Abxis Co Ltd
42.4%
ATXS
-17 568%

FCF Margin

Isu Abxis Co Ltd
0.7%
ATXS
-17 042.9%

ROE

Isu Abxis Co Ltd
29.1%
ATXS
-43.1%

ROA

Isu Abxis Co Ltd
18.9%
ATXS
-39.2%

ROIC

Isu Abxis Co Ltd
47.1%
ATXS
-462.1%

ROCE

Isu Abxis Co Ltd
14.2%
ATXS
-45.9%

Solvency Comparison

No Stocks Selected

Compare company's equity waterfall with its competitors.

Select Stocks to Compare
Balance Sheet Comparison
No Stocks Selected

Compare company's balance sheet with its competitors.

Select Stocks to Compare

Stocks Performance

Stocks Performance
086890, ATXS

Loading
086890
ATXS
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
086890, ATXS

Loading
086890
ATXS
Difference
www.alphaspread.com

Performance By Year
086890, ATXS

Loading
086890
ATXS
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Compare 086890 to other stocks
PNEXF
Pharnext SCA
More expensive
vs Isu Abxis Co Ltd
ABBV
Abbvie Inc
More expensive
vs Isu Abxis Co Ltd
AMGN
Amgen Inc
More expensive
vs Isu Abxis Co Ltd
GILD
Gilead Sciences Inc
More expensive
vs Isu Abxis Co Ltd
Unlock Full Access to Alpha Spread
Create Free Account
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett